A month has gone by since the last earnings report for Globus Medical (GMED) . Shares have lost about 9.2% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Globus Medical due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Globus Medical, Inc. before we dive into how investors and analysts ...

AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. “We are grateful for John’s many contributions, especially during the merger with NuVasive and his service on the Nominati ...

Over the past 12 months, the application of generative AI (GenAI) in the Medical Instruments industry has moved from experimental to operational use, enhancing diagnostics, patient monitoring and intervention workflows. GenAI could transform health care through synthetic medical imaging, disease progression modeling sand drug molecule design with simulated effect, according to a 2025 U.S. National Science Foundation report. At the same time, regulatory bodies are adapting. The European Union AI Act (EU AI A ...

I am an investment author with passion for finance and global markets. I enjoy gearing toward economic analysis, specifically on a macro level. Through current and forward looking market trends, fundamental and technical analysis, my goal is to provide investors and readers with the tools and knowledge to make informed and confident investment decisions. I am always open to feedback and hope you enjoy my writing!Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the co ...

Industry Overview - The U.S. medical instrument industry has stabilized entering 2026 after years of volatility due to inflation, rising interest rates, and uneven hospital spending, with procedure volumes normalizing post-pandemic [1] - Providers are cautious on capital budgets, focusing on productivity, reliability, and total cost of ownership [1] - The Medical - Instruments industry is ranked in the top 35% of the Zacks Industry Rank, indicating expected outperformance over the next three to six months [2] Company Highlights Intuitive Surgical Inc. (ISRG) - ISRG is integrating AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics and providing real-time decision support [4][5] - The company has an expected revenue growth rate of 14.9% and earnings growth rate of 12.7% for the current year, with a Zacks Consensus Estimate for earnings improving by 0.5% [6] - The short-term average price target indicates a potential increase of 26% from the last closing price of $493.56, with a maximum upside of 52% [8] Globus Medical Inc. (GMED) - GMED's acquisition of Nevro and the merger with NuVasive are expected to strengthen its position in the musculoskeletal space and expand its product portfolio [9][10] - The company anticipates revenue growth of 8% and earnings growth of 7.5% for the current year, with earnings estimates improving by 6.7% [10] - The short-term average price target suggests a 24.7% increase from the last closing price of $87.81, with a maximum upside of 40.1% [11] Edwards Lifesciences Corp. (EW) - EW's Surgical Structural Heart business is benefiting from strong adoption of premium surgical technologies, with a focus on developing a comprehensive structural heart disease portfolio [12][13] - The expected revenue growth rate is 9.6% and earnings growth rate is 14.8% for the current year, with earnings estimates improving by 2.1% [14] - The short-term average price target indicates a 14% increase from the last closing price of $84.26, with a maximum upside of 30.5% [14] Alcon Inc. (ALC) - ALC is leveraging its Surgical and Vision Care segments for growth, with innovative products driving category leadership [15][16] - The expected revenue growth rate is 7.1% and earnings growth rate is 12.1% for the current year, with earnings estimates improving by 2.1% [16] - The short-term average price target suggests a 13.9% increase from the last closing price of $81.85, with a maximum upside of 36.8% [17] IRADIMED Corp. (IRMD) - IRMD specializes in MRI-compatible products and serves hospitals and outpatient imaging centers [18][19] - The expected revenue growth rate is 10.8% and earnings growth rate is 8.8% for the current year, with earnings estimates remaining stable [20] - The short-term average price target indicates a 19.9% increase from the last closing price of $100.18, with a maximum upside of 20% [20]

Core Viewpoint - Globus Medical (GMED) has shown a recent downtrend, losing 8.8% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding, which is a bullish signal for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that despite a downtrend, buyers are starting to emerge [4][5]. - The occurrence of this pattern at the bottom of a downtrend signals that bears may be losing control, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for GMED, which is a bullish indicator as it correlates strongly with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for GMED has increased by 8.9%, indicating that analysts expect better earnings than previously predicted [8]. - GMED holds a Zacks Rank of 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Invesco Ltd‘s “Small Cap Value Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The Invesco Small Cap Value Fund reported strong results for Q4 2025, outperforming its Russell 2000 Value Index benchmark as Class A shares delivered a quarterly return of 6.79%, compared to the benchmark’s 3.26%, with stock selection in the Information Technology sector contributing approximately 2.90% to relative performance while health care and financials detracted. For the full year, ...

Core Insights - Globus Medical, Inc. (GMED) is increasing its market share in the musculoskeletal solutions sector, driven by strong performance in implantable devices, biologics, accessories, and unique surgical instruments used in various spinal, orthopedic, and neurosurgical procedures [1][4] - The company has shown consistent innovation through a rapid pace of new product introductions, contributing to its solid financial health [1][7] - Despite these strengths, macroeconomic challenges and competitive disadvantages pose risks to GMED's operations [1][9] Financial Performance - Over the past year, GMED's stock has risen by 14.7%, outperforming the industry, which declined by 7.1%, while the S&P 500 composite increased by 19.3% [2] - GMED has a market capitalization of $12.55 billion and an earnings yield of 4.7%, significantly higher than the industry's 0.8% [2] - The company has exceeded earnings estimates in three of the last four quarters, with an average surprise of 18.8% [2] Business Growth - The U.S. Spine business grew by 10% year over year in the fourth quarter, supported by strong retention in the sales team and effective product cross-selling [4][5] - The trauma business experienced a 27% sales growth in the same quarter, driven by the uptake of legacy trauma products and new offerings like the ANTHEM Elbow Fracture System [5][8] - The integration of NuVasive has accelerated the pace of product launches, with significant new products introduced in 2025 [6] Financial Stability - At the end of the fourth quarter of 2025, GMED reported cash and cash equivalents of $526.2 million and no short-term or long-term debt, indicating strong financial stability [7][8] Macroeconomic Challenges - GMED faces macroeconomic headwinds, including interest rate fluctuations, inflation, and financial market volatility, which are negatively impacting its operations [9] - SG&A expenses rose by 25.8% year over year in the fourth quarter of 2025, reflecting the pressures from sustained inflation [9] Future Estimates - The Zacks Consensus Estimate for GMED's 2026 earnings per share (EPS) has increased by 10% to $4.28, with revenue estimates at $3.17 billion, indicating an 8% rise from the previous year [10]

Core Viewpoint - Globus Medical (GMED) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have a strong correlation with near-term stock price movements [4][6]. - For Globus Medical, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to a rise in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10]. Earnings Estimate Revisions for Globus Medical - Analysts have raised their earnings estimates for Globus Medical, with the Zacks Consensus Estimate increasing by 13.4% over the past three months [8]. - The expected earnings per share for the fiscal year ending December 2026 is $4.28, reflecting no year-over-year change [8].

Core Viewpoint - The growth of medical device companies in Europe and the US heavily relies on mergers and acquisitions, as exemplified by Globus Medical's recent performance and strategic acquisitions [2][4]. Financial Overview - In Q4 2025, Globus Medical reported revenue of $826.4 million, a year-on-year increase of 25.7%, exceeding Wall Street expectations; non-GAAP EPS reached $1.28, up 52.1% year-on-year [4]. - For the full year 2025, the company achieved revenue of $2.939 billion, a 16.7% increase, with non-GAAP EPS of $3.98, reflecting a 30.8% growth [4]. - The management attributed the strong performance to the integration of the acquisitions of NuVasive and Nevro, indicating a validation of their merger integration capabilities [4][5]. Horizontal Integration - The acquisition of NuVasive in 2023 is a classic example of horizontal integration, achieving approximately $200 million in synergy, exceeding initial targets by $30 million and completing integration nearly a year ahead of schedule [7]. - Globus's strategy involved retaining core sales capabilities, promoting cross-selling, and optimizing cost structures, which is a profit expansion model driven by scale [8]. Cross-Sector Expansion - The acquisition of Nevro represents a strategic extension into a new sector, with Nevro's revenue of $409 million in FY 2024 but a net loss of $113 million [13]. - Globus's integration plan for Nevro includes stabilizing the sales team, managing execution risks, and enhancing overall profitability, with expectations for positive EPS contribution by Q1 2027, ahead of schedule [13][17]. Core Business Validation - Globus's US spinal business grew by 10% year-on-year in Q4, indicating that core operations remained strong despite the focus on merger integrations [19]. - Successful merger integration must be built on a solid core business foundation, as evidenced by Globus's ability to maintain growth while managing acquisitions [20]. International Strategy - In Q4, Globus's international revenue grew by 19%, but management emphasized a focus on deepening existing markets rather than expanding into new ones [21]. - This approach contrasts with many Chinese medical device companies that are pursuing rapid international expansion without sufficient depth in existing markets [22]. Summary Insights for Chinese Medical Device Industry - M&A capabilities are becoming a core factor in valuation, as the market shifts focus from single product stories to integration and profit realization capabilities [24]. - The next generation of industry leaders is likely to emerge from successful M&A integrations rather than reliance on standout products [25]. - Platform-based expansion is more sustainable than single-product strategies, as evidenced by the need for Chinese companies to transition from product-driven to platform-driven models [25][26].